| Vol. 9.04 – 2 February, 2021 |
| |
|
|
| Synovial sarcoma (SyS) is an aggressive neoplasm driven by the SS18–SSX fusion, and is characterized by low T cell infiltration. Scientists studied the cancer-immune interplay in SyS using an integrative approach that combined single-cell RNA sequencing, spatial profiling and genetic and pharmacological perturbations. [Nature Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators identified that expression of tumor stanniocalcin 1 correlated with immunotherapy efficacy and was negatively associated with patient survival across diverse cancer types. [Cancer Cell] |
|
|
|
| Researchers analyzed data from 44 patients with elapsed or refractory B-cell malignancies who received CD19-targeted chimeric antigen receptor-engineered on a Phase I/II trial. [Blood] |
|
|
|
| The authors applied hypothesis-generating network transcriptomics to CD8+ cells isolated from patients in relapsing/remitting multiple sclerosis, identifying a signature reflecting expansion of a subset of CD8+ natural killer (NK) cells associated with favorable outcome. [Nature Communications] |
|
|
|
| In a retrospective cohort study of 1714 patients with 16 different cancer types treated with immune checkpoint inhibitors, scientists showed that higher neutrophil-to-lymphocyte ratio was significantly associated with poorer overall and progression-free survival. [Nature Communications] |
|
|
|
| Investigators evaluated human leucocyte antigen (HLA)‐expressing class Ia and class II of their human‐induced pluripotent stem cells and their differentiated cells into embryoid bodies, cardiomyocytes and mesenchymal stem cells. [Cell Proliferation] |
|
|
|
| The effect of recombinant adiponectin (APN) and APN-containing sera was assessed on functional responses of normal human peripheral blood myeloid and T cells and on human central nervous system-derived microglia. [Multiple Sclerosis Journal] |
|
|
|
| Scientists demonstrated that the clinically approved iron chelator deferasirox exerted an anti‐tumoral effect in mantle cell lymphoma cell lines and patient cells. [British Journal of Haematology] |
|
|
|
| Investigators studied a convenience sample of 63 children presenting to a pediatric emergency department with respiratory symptoms. T cell subsets in the nasal mucosa were analyzed by flow cytometry. [Pediatric Research] |
|
|
|
|
| The authors discuss new data on the major genomic and metabolic characteristics of myeloid-derived suppressor cells. [Nature Reviews Immunology] |
|
|
|
| Scientists cover the accumulating data about the roles of the bromodomain and extraterminal domain (BET) family in innate immunity, and discuss the attractive prospect of manipulating the BET family as a new treatment for disease. [Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators summarize the prevalence and molecular mechanisms behind human leukocyte antigen class I (HLA-I) loss in colorectal cancer (CRC), and discuss HLA-I expression/loss in the context of the newly identified CRC molecular subtypes. [Cellular & Molecular Immunology] |
|
|
|
|
| Immudex has announced the launch of dCODE Dextramer® reagents. These DNA barcoded MHC Dextramer® reagents are designed to be compatible with the BD Rhapsody™ system to be used for multiplexing, allowing the identification of many different T-cell specificities in the same sample. [Immudex (Life Science Newswire, Inc.)] |
|
|
|
|
| February 3 – 5, 2021 Virtual |
|
|
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| University of Pennsylvania – Philadelphia, Pennsylvania, United States |
|
|
|
| The University of Utah School of Medicine – Salt Lake City, Utah, United States |
|
|
|
| Systimmune, Inc. – Redmond, Washington, United States |
|
|
|
|